TY - JOUR
T1 - Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity
AU - Wiles, Nicola J.
AU - Lunt, Mark
AU - Barrett, Elizabeth M.
AU - Bukhari, Marwan
AU - Silman, Alan J.
AU - Symmons, Deborah P M
AU - Dunn, Graham
PY - 2001/5
Y1 - 2001/5
N2 - Objective. To determine the effect of treatment with disease-modifying antirheumatic drugs (DMARDs) and/or steroids on 5-year disability outcome in patients with inflammatory polyarthritis. Methods. Three hundred eighty-four patients registered by the Norfolk Arthritis Register (a primary care-based observational cohort) were followed up for 5 years. Treatment details and Health Assessment Questionnaire (HAQ) scores were recorded annually. Logistic regression was used to model differences in baseline factors associated with the start of DMARDs and/or steroids within 12 months of baseline. Based on this model, each subject was given a probability of starting treatment ("propensity score"). A second model compared the odds of disability (HAQ score ≥1.00) in treated and untreated patients, adjusting for differences in disease severity using the propensity score. Results. Unadjusted analysis suggested that patients who received treatment had an increased odds of a worse outcome compared with those who did not receive treatment. When adjusted for differences in disease severity, using the propensity score, early treatment (within 6 months of symptom onset) was associated with a similar odds of disability at 5 years compared with those not treated (odds ratio 0.71; 95% confidence interval 0.34, 1.44). In contrast, starting treatment later (≥6 months) was associated with a 2-fold increased odds of having a HAQ score ≥1.00 at 5 years. Conclusion. The propensity score was a useful method of adjusting for "confounding by indication" in observational studies. Furthermore, this study showed that early treatment with DMARDs/steroids (within 6 months of symptom onset) reduced the odds of disability 5 years later to a level comparable with that of patients judged clinically as not requiring treatment.
AB - Objective. To determine the effect of treatment with disease-modifying antirheumatic drugs (DMARDs) and/or steroids on 5-year disability outcome in patients with inflammatory polyarthritis. Methods. Three hundred eighty-four patients registered by the Norfolk Arthritis Register (a primary care-based observational cohort) were followed up for 5 years. Treatment details and Health Assessment Questionnaire (HAQ) scores were recorded annually. Logistic regression was used to model differences in baseline factors associated with the start of DMARDs and/or steroids within 12 months of baseline. Based on this model, each subject was given a probability of starting treatment ("propensity score"). A second model compared the odds of disability (HAQ score ≥1.00) in treated and untreated patients, adjusting for differences in disease severity using the propensity score. Results. Unadjusted analysis suggested that patients who received treatment had an increased odds of a worse outcome compared with those who did not receive treatment. When adjusted for differences in disease severity, using the propensity score, early treatment (within 6 months of symptom onset) was associated with a similar odds of disability at 5 years compared with those not treated (odds ratio 0.71; 95% confidence interval 0.34, 1.44). In contrast, starting treatment later (≥6 months) was associated with a 2-fold increased odds of having a HAQ score ≥1.00 at 5 years. Conclusion. The propensity score was a useful method of adjusting for "confounding by indication" in observational studies. Furthermore, this study showed that early treatment with DMARDs/steroids (within 6 months of symptom onset) reduced the odds of disability 5 years later to a level comparable with that of patients judged clinically as not requiring treatment.
KW - Treatment Outcome
U2 - 10.1002/1529-0131(200105)44:5<1033::AID-ANR182>3.0.CO;2-G
DO - 10.1002/1529-0131(200105)44:5<1033::AID-ANR182>3.0.CO;2-G
M3 - Article
SN - 2151-464X
VL - 44
SP - 1033
EP - 1042
JO - Arthritis Care & Research
JF - Arthritis Care & Research
IS - 5
ER -